Brief: In8bio Announces Updates From Phase 1 Trial Of Genetically Modified Gamma-Delta T Cell Therapy
06/01/2022 12:41
Jan 6 (Reuters) - IN8BIO, Inc. INAB.O :
* IN8BIO ANNOUNCES CLINICAL UPDATES FROM THE PHASE 1
CLINICAL
TRIAL OF ITS GENETICALLY MODIFIED GAMMA-DELTA T CELL THERAPY IN
NEWLY DIAGNOSED GLIOBLASTOMA MULTIFORME
* IN8BIO, INC. - PATIENT RECRUITMENT AND TREATMENT ARE
ONGOING
WITH ANTICIPATED COMPLETION OF ENROLLMENT IN 2022
Source text for Eikon: ID:nGNXdsSXR
Further company coverage: INAB.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on IN8bio
See all newsIN8bio, Inc. reports results for the quarter ended June 30 - Earnings Summary
Biopharma firm IN8bio's Q2 net loss narrows as expenses decline
IN8bio Inc expected to post a loss of 37 cents a share - Earnings Preview
Brief: IN8BIO - Enters Capital On Demand Sales Agreement With Jonestrading For ATM Offering
IN8bio Q1 net loss narrows as R&D expenses fall